Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
Portfolio Pulse from Lara Goldstein
Australian biotech startup Psylo has entered into a sponsored research agreement with Japanese pharmaceutical company Daiichi Sankyo (OTC:DSNKY) to advance the development of antidepressant psychiatric medicines. Psylo will leverage its expertise in neuropsychiatric therapies and Daiichi Sankyo's experience in drug discovery and clinical development to research potential treatments for chronic mental illnesses.
June 27, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daiichi Sankyo's partnership with Psylo to develop antidepressant psychiatric medicines could potentially lead to the discovery of novel treatments for chronic mental illnesses, which could boost the company's product portfolio and future revenues.
The partnership with Psylo could potentially lead to the discovery of novel treatments for chronic mental illnesses. If successful, this could significantly enhance Daiichi Sankyo's product portfolio and future revenues, positively impacting the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100